Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential
The DOI matches its Crossref record.
Abstract
Recent data suggest that signal transduction may have a critical role in the development and regulation of the metastatic phenotype. Here, we investigated the role of c-Src activation in the process of human colon cancer metastasis to the liver. Our data, derived from two different sets of human colon cancer cell line metastatic variants, suggest that not only do highly-metastatic cells display constitutively elevated c-Src protein kinase activity when compared to poorly metastatic cells, but also that receptor tyrosine kinases participate in the ligand-activation of c-Src above basal levels. Specifically, the epidermal growth factor receptor (EGFR), p185HER2/Neu and the hepatocyte growth factor receptor (c-Met) appear to be linked to the process because they preferentially activate c-Src in highly-metastatic cells. EGFR was found to associate with c-Src in colon cancer cells and specific inhibitors of the EGFR resulted in a reduction of c-Src activity to basal levels. In addition, c-Src transfectants displayed partially-activated EGFRs, suggesting a feedback role for c-Src in the regulation of the EGFR. p185HER2/Neu was also identified in immunocomplexes of c-Src following ligand activation of the EGFR, but only in highly-metastatic cells. Collectively, these observations suggest a paradigm whereby c-Src interacts with multiple cell-surface growth factors in a catalytic fashion for the development of tumor cells with metastatic potential.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the SRC activation signature score was significantly associated with metastasis and primary tumor stage I-IV progression (Fig. 2g,h), in agreement with previous studies in CRC [37–40].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [39]
Citations
Cited by
Items 101–200 of 204
Kinase Inhibitors and Ovarian Cancer
Katopodis, P., Chudasama, D., Wander, G., Sales, L., Kumar, J., Pandhal, M., Anikin, V., Chatterjee, J., Hall, M., & Karteris, E. (2019) · Cancers · doi:10.3390/cancers11091357 · Cited by 34
“Nintedanib: Nintedanib is an oral inhibitor of VEGFRs, PDGFRs, and fibroblast growth factor receptors (FGFRs) (Table 2) [36].”
BackgroundDrosophila as a Tool for Personalized Medicine: A Primer
Kasai, Y., & Cagan, R. L. (2010) · Personalized Medicine · doi:10.2217/pme.10.65 · Cited by 38
“Pairing these not only synergizes with respect to proliferation, but also shows emergent tendencies for transformed cells to undergo metastasis-like migration [28– 33].”
BackgroundOlszewska-Pazdrak, B., Townsend, C. M., & Hellmich, M. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400208200 · Cited by 33
Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment
Heiska, L., Melikova, M., Zhao, F., Saotome, I., McClatchey, A. I., & Carpén, O. (2011) · Oncogene · doi:10.1038/onc.2011.207 · Cited by 32
“, 2002), but increased Src levels and activating mutations are detected as colon tumors progress (Talamonti et al., 1993; Cartwright et al., 1994; Mao et al., 1997; Irby et al., 1999).”
BackgroundInvolvement of c‐Src in Carcinoma Cell Motility and Metastasis
Sakamoto, M., Takamura, M., Ino, Y., Miura, A., Genda, T., & Hirohashi, S. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01184.x · Cited by 32
Iterative Microarray and RNA Interference–Based Interrogation of the Src-Induced Invasive Phenotype
Irby, R., Malek, R. L., Bloom, G., Tsai, J., Letwin, N. E., Frank, B. C., Verratti, K. J., Yeatman, T. J., & Lee, N. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3609 · Cited by 33
“Src is activated by a number of receptor tyrosine kinases, such as epidermal growth factor receptor (6, 7) and insulin-like growth factor receptor (8).”
BackgroundSelf-citationKurata, A., Katayama, R., Watanabe, T., Tsuruo, T., & Fujita, N. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00874.x · Cited by 35
Wen, X., Li, C., Zong, Y.-Y., Yu, C., Xu, J., Han, D. K., & Zhang, G.-Y. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.08.006 · Cited by 31
Milkiewicz, K. L., Marsilje, T. H., Woodworth, R. P., Bifulco, N., Hangauer, M. J., & Hangauer, D. G. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00040-8 · Cited by 30
Li, H., Chen, Y., Wen, J., & Zhou, H. (2017) · Oncology Letters · doi:10.3892/ol.2017.6670 · Cited by 31
“Met, identified as a transcriptional target of MACC1, is associated with CRC metastasis (121-129).”
Lee, J., Maa, M., Yu, H., Wang, J., Yen, C., Wang, S., Chen, Y., Liu, Y., Jin, Y., & Leu, T. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20117 · Cited by 31
Self-citationPathways of metastasis suppression in bladder cancer
Said, N. A., & Theodorescu, D. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9197-4 · Cited by 29
Watanabe, S., Yoshida, T., Kawakami, H., Takegawa, N., Tanizaki, J., Hayashi, H., Takeda, M., Yonesaka, K., Tsurutani, J., & Nakagawa, K. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0351 · Cited by 31
“Although the specific mechanism underlying Src inhibition is not fully understood, it is possible that Src has a universal role in mediating multiple resistance pathways, since SFKs are transducers of mitogenic signals originating from a number of receptor tyrosine kinases such as EGFR, human epidermal growth factor r…”
BackgroundSynthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives
Chand, K., Prasad, S., Tiwari, R. K., Shirazi, A. N., Kumar, S., Parang, K., & Sharma, S. K. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.02.001 · Cited by 28
“Increased Src activity elevates the cell growth rate and reduces adhesion between cells, leading to the development of metastatic potential of cells [7-9].”
BackgroundPrice, D. J., & Jorgensen, W. L. (2001) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1012266200343 · Cited by 28
Najar, A. G., Pashaei‐Asl, R., Omidi, Y., Farajnia, S., & Nourazarian, A. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.1.495 · Cited by 29
“Also, there is a crosstalk association between STAT5 signaling and MAPK pathway in colorectal cancer (Mao et al., 1997).”
BackgroundStrickler, J. H., McCall, S. J., Nixon, A. B., Brady, J. C., Pang, H., Rushing, C. N., Cohn, A. L., Starodub, A., Arrowood, C., Haley, S. T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0042-9 · Cited by 27
“Src is a non-receptor protein tyrosine kinase involved in cell adhesion, invasiveness, motility, and angiogenesis [27, 35].”
Vickers, S. M., Huang, Z., MacMillan-Crow, L.-A., Greendorfer, J. S., & Thompson, J. A. (2002) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(02)00036-7 · Cited by 30
Stenzinger, A., Schreiner, D., Reiners-Koch, P.-S., Hofer, H. W., & Wimmer, M. A. (2009) · International review of cytology · doi:10.1016/s1937-6448(09)75006-3 · Cited by 31
Hirsch, C. L., Smith‐Windsor, E. L., & Bonham, K. (2006) · International Journal of Cancer · doi:10.1002/ijc.21383 · Cited by 26
“Interestingly, highly metastatic cells display constitutively elevated c-Src kinase activity compared to poorly metastatic cells in colon neoplasias.(10,11) Furthermore, this elevated c-Src expression and enhanced kinase”
BackgroundBoudný, V., & Nakano, S. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600080 · Cited by 27
“Specifically, c-Src has been found to be highly activated in colon cancer metastasized to the liver (Mao et al, 1997) and mutation in the regulatory domain of c-Src has been reported as a mechanism of Src activation in human colon cancer (Irby et al, 1999).”
BackgroundWelman, A., Cawthome, C., Ponce-Perez, L., Barraclough, J., Danson, S., Murray, S., Cummings, J., Allen, T. D., & Dive, C. (2006) · Neoplasia · doi:10.1593/neo.06475 · Cited by 26
“In more than 70% of colorectal cancers, the levels and activity of c-Src are upregulated 5 to 40 times compared to neighboring normal mucosa and increase steadily in the course of tumor development, reaching the highest level in metastatic malignancies [2,8–11].”
BackgroundDong, S., Khoo, A., Wei, J., Bowser, R. K., Weathington, N. M., Xiao, S., Zhang, L., Ma, H., Zhao, Y., & Zhao, J. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00132.2014 · Cited by 27
“The c-Src tyrosine kinase has been implicated in the development and progression of various human cancers of the colon, breast, pancreas, and brain (7, 28, 50).”
BackgroundMorrow, C. J., Ghattas, M. A., Smith, C., Bönisch, H., Bryce, R. A., Hickinson, D. M., Green, T. P., & Dive, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0694 · Cited by 28
Activation of β-catenin–TCF-mediated transcription by non-receptor tyrosine kinase v-Src
Haraguchi, K., Nishida, A., Ishidate, T., & Akiyama, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.021 · Cited by 25
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
Self-citationDenk, D., Ramakrishnan, M., Conche, C., Pallangyo, C. K., Pesic, M. H., Ceteci, F., Kennel, K. B., Kirisözü, A. C., Engel, E., Mohs, K., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.005 · Cited by 25
HOU, J., Cui, A., Song, P., Hua, H. M., Luo, T. L., & Jiang, Y. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2736 · Cited by 26
“While Src may act downstream of epidermal growth factor receptor (EGFR), it also regulates the activity of EGFR (18).”
Lee, H.-J., Kim, E., Jee, B., Hahn, J.-H., Han, K., Jung, K. C., Park, S. H., & Lee, H. (2002) · Experimental & Molecular Medicine · doi:10.1038/emm.2002.26 · Cited by 24
“…have reported elevated expression and activity of FAK and src kinase in advanced progression stages of several types of human cancer including colon, thyroid, prostate and ovarian cancers (Talamonti et al., 1993; Owens et al., 1996; Tremblay et al., 1996; Mao et al., 1997; Judson et al., 1999).”
BackgroundKumar, A., Wang, Y., Lin, X., Sun, G., & Parang, K. (2007) · ChemMedChem · doi:10.1002/cmdc.200700074 · Cited by 24
A p130 Cas tyrosine phosphorylated substrate domain decoy disrupts v-Crk signaling
Kirsch, K. H., Kensinger, M. H., Hanafusa, H., & August, A. (2002) · BMC Cell Biology · doi:10.1186/1471-2121-3-18 · Cited by 24
“Indeed, colon cancer cells with high metastatic potential have elevated levels of Src activity or activating mutations in the Src gene [4,5].”
BackgroundNovel Protein Kinase Inhibitors: SMART Drug Design Technology
Sawyer, T. K., Bohacek, R. S., Metcalf, C. A., Shakespeare, W. C., Wang, Y., Sundaramoorthi, R., Keenan, T. P., Narula, S. S., Weigele, M., & Dalgarno, D. C. (2003) · BioTechniques · doi:10.2144/sawyerjun03revised · Cited by 24
Lee, T., Tseng, Y.-C., Chang, W., Chen, Y., Kao, Y.-R., Chou, T., Ho, C., & Wu, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19647 · Cited by 25
“Moreover, SRC that is known to interact with EGFR [21, 22] has recently been reported to regulate YAP1 stability.”
BackgroundOno, M., Higuchi, T., Takeshima, M., Chen, C., & Nakano, S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.071 · Cited by 25
Nourazarian, A., Pashaei‐Asl, R., Omidi, Y., & Najar, A. G. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.5.2235 · Cited by 22
“In addition, c-Src is over-expressed in a HT29 cell line of colon cancer and plays an important role in the development of metastatic stage of primary human colorectal cancer (Talamonti et al, 1993; Termuhlen et al., 1993; Mao et al., 1997).”
BackgroundRecent advances in the discovery of Src kinase inhibitors
Parang, K., & Sun, G. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.9.1183 · Cited by 22
“, colon, rectal, or stomach cancer) [11,12], osteoporosis and inflammation-mediated bone loss [13], cardiovascular disorders [14,15], and immune system dysfunction [16-19].”
BackgroundClinical significance of Src expression and activity in human neoplasia.
Chatzizacharias, N. A., Kouraklis, G. P., Giaginis, C., & Theocharis, S. E. (2012) · PubMed · doi:10.14670/hh-27.677 · Cited by 26
“677 http://www.hh.um.es Histology and Histopathology Cellular and Molecular Biology Abbrevations: Arg: arginine, Csk: c-Src tyrosine kinase, EGFR: Epidermal Growth Factor Receptor, ER: estrogen receptor, FAK: Focal Adhesion Kinase, FAs: focal adhesions, FGFR: Fibroblast Growth Factor Receptor, HGF: Hepatocyte Growth F…”
BackgroundInfluentialSRC inhibition represents a potential therapeutic strategy in liposarcoma
Sievers, E., Trautmann, M., Kindler, D., Huss, S., Gruenewald, I., Dirksen, U., Renner, M., Mechtersheimer, G., Pédeutour, F., Åman, P., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29645 · Cited by 21
Ono, M., Takeshima, M., Nishi, A., Higuchi, T., & Nakano, S. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1797835 · Cited by 22
“Moreover, Src is highly activated in colon cancer metastasized to the liver (18).”
BackgroundSun, M., Zheng, Y., Wei, H., Chen, J., Cai, J., & Ji, M. (2009) · QSAR & Combinatorial Science · doi:10.1002/qsar.200860107 · Cited by 20
Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway
Yun, U.-J., Sung, J. Y., Park, S.-Y., Ye, S., Shim, J., Lee, J., Hibi, M., Bae, Y., & Kim, Y.-N. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.50 · Cited by 20
Requirement of km23 for TGFβ-mediated growth inhibition and induction of fibronectin expression
Jin, Q., Ding, W., Staub, C. M., Gao, G., Tang, Q., & Mulder, K. M. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.02.004 · Cited by 19
Poon, C. L. C., Brumby, A. M., & Richardson, H. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061585 · Cited by 20
Teli, G., Pal, R., Maji, L., Matada, G. S. P., & Sengupta, S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2205943 · Cited by 19
“Specifically, in highly metastatic human colon cancer cells, EGFR selectively activates c-Src (Mao et al., 1997).”
Backgroundc-Src dependency of NSAID-induced effects on NF- B-mediated apoptosis in colorectal cancer cells
Brady, R. R. W., Loveridge, C. J., Dunlop, M. G., & Stark, L. A. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr077 · Cited by 19
Preubiquitinated chimeric ErbB2 is constitutively endocytosed and subsequently degraded in lysosomes
Vuong, T. T., Berger, C., Bertelsen, V., Rødland, M. S., Stang, E., & Madshus, I. H. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.10.010 · Cited by 15
Lotz, M. M., Wang, H. H.-F., Cance, W. G., Matthews, J. B., & Pories, S. E. (2003) · Journal of Surgical Research · doi:10.1016/s0022-4804(02)00100-2 · Cited by 15
“Studies have established a biochemical relationship between EGFR on the surface of carcinoma cells and c-Src activity within the cell that leads to alterations in the actin cytoskeleton and ultimately cell motility [8–10].”
BackgroundSuppression of anoikis by v‐Src but not by activated c‐H‐Ras in human gallbladder epithelial cells
Hisano, C., Tanaka, R., Fujishima, H., Ariyama, H., Tsuchiya, T., Tatsumoto, T., Mitsugi, K., Nakamura, M., & Nakano, S. (2003) · Cell Biology International · doi:10.1016/s1065-6995(03)00032-5 · Cited by 14
“Recently, Owens et al. (1995) demonstrated that FAK mRNA over-expression and increased levels of p125FAK are correlated with the invasive potential of human colon cancers, where activation of Src is highly associated with metastatic potential to the liver (Mao et al., 1997; Talamonti et al., 1993).”
BackgroundSun, M., Zheng, Y., Wei, H., Chen, J., & Ji, M. (2009) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360802632906 · Cited by 12
“, colon, rectal, or stomach cancer) [2,3], osteoporosis [4], cardiovascular disorders [5] and immune system dysfunction [6].”
BackgroundNovel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy
Sawyer, T. K. (2007) · Topics in medicinal chemistry · doi:10.1007/7355_2006_010 · Cited by 14
Jackson, J. L., & Young, M. R. I. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1024012000009 · Cited by 11
Looking to the Future: Advances in the Management of Hormone-Refractory Prostate Cancer
Trachtenberg, J., & Blackledge, G. R. P. (2002) · European Urology Supplements · doi:10.1016/s1569-9056(02)00087-8 · Cited by 10
Khan, M. R. U. Z., & Trivedi, V. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2220036 · Cited by 9
“…and migration (S. Zhang & Yu, 2012). c-Src was found to be down-regulated in DLD1 cells upon treatment with HCAE after 24 and 48 h of treatment (Figure 7c & d). c-Src in CRCs is activated by EGFR by forming a Src/EGFR/NADPH complex that activates the overexpression of c-Met (Mao et al., 1997).”
BackgroundTakahashi, M., Araki, T., Yashima, H., Nagamine, A., Nagano, D., & Yamamoto, K. (2023) · Oncology Letters · doi:10.3892/ol.2023.14116 · Cited by 10
Arulanandam, R., Geletu, M., & Raptis, L. H. (2010) · PubMed · Cited by 9
Bendinelli, P., Maroni, P., Matteucci, E., & Desiderio, M. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.06.004 · Cited by 9
“c-Src activity is higher in metastasis from colon cancer than in both primary tumor tissue and in cells with limited metastatic potential [2–4].”
Backgroundv-Src-mediated transformation suppresses the expression of focal adhesion protein vinexin
Umemoto, T., Inomoto, T., Ueda, K., Hamaguchi, M., & Kioka, N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.017 · Cited by 9
Screening Dys-Methylation Genes and Rules for Cancer Diagnosis by Using the Pan-Cancer Study
Zhang, Y., Zeng, T., Pan, X., Guo, W., Gan, Z., Zhang, Y., Huang, T., & Cai, Y. (2019) · IEEE Access · doi:10.1109/access.2019.2961402 · Cited by 10
“The combined alteration of EGFR and SRC expression in fibroblasts improves the levels of tumorigenicity [45].”
BackgroundHu, J., Hameed, M., Agaram, N. P., Whiting, K. A., Qin, L., Villano, A. M., O’Connor, R., Rozenberg, J. M., Cohen, S., Prendergast, K. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2313 · Cited by 8
Wang, H.-C., Huo, Y., & Lee, W. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02077-3 · Cited by 9
Momparler, R. L., & Bovenzi, V. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200005)183:2<145::aid-jcp1>3.0.co;2-v · Cited by 387
Price, D. J., & Jorgensen, W. L. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00401-7 · Cited by 8
Sobani, Z. A., Sawant, A. S., Jafri, M., Correa, A. K., & Şahin, İ. H. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i5.340 · Cited by 10
Manchanda, P., Parshad, B., Kumar, A., Tiwari, R. K., Shirazi, A. N., Parang, K., & Sharma, S. K. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201600390 · Cited by 7
Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Events
Ly, Q. P., & Yeatman, T. J. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_10 · Cited by 7
Self-citationSrc tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Rothschild, S. I., & Gautschi, O. P. (2012) · Clinical Investigation · doi:10.4155/cli.12.27 · Cited by 6
Emerging therapies for colorectal cancer
Hezel, A. F., & Ryan, D. P. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.867 · Cited by 6
“Increased SRC activity has been found in CRC and seems to relate to metastatic potential [85-87].”
BackgroundMultiplex Analysis of Src Family Kinase Signaling by Microbead Suspension Arrays
Campbell, M., Lie, W., Zhao, J., Hayes, D., Mistry, J., Kung, H.-J., Luciw, P. A., & Khan, I. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2009.0255 · Cited by 7
The Role of Oncogene Activation in Tumor Progression
Gray, M. J., & Gallick, G. E. (2010) · Springer eBooks · doi:10.1007/978-90-481-3725-1_2 · Cited by 6
Implications for Src Kinases in Hematopoiesis: Signal Transduction Therapeutics
Sinha, S., & Corey, S. J. (1999) · Stem Cells and Development · doi:10.1089/152581699319920 · Cited by 4
Olive Leaves and Mill Waste Exert Anti-Tumoral Properties in Hepatoma Cell Line
(2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000170 · Cited by 2
Protein Kinases and Protein Phosphatases in Signal Transduction Pathways
Sawyer, T. K. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00070-5 · Cited by 5
v-Src Transformation Is Mediated through Farnesylated Proteins
Teng, S., Sun, J., Irby, R., Hamilton, A. D., Sebti, S., & Yeatman, T. J. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6184 · Cited by 3
“Activated Src kinase activity and Src overexpression have both been observed in a number of human malignancies including pancreatic and colon cancer [1–3].”
BackgroundSelf-citationParent, L. J. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0016-5_28 · Cited by 3
Khan, M. R. U. Z., & Trivedi, V. (2023) · Pharmacognosy Research · doi:10.5530/pres.15.4.076 · Cited by 1
Sawyer, T. K., Bohacek, R. S., Shakespeare, W. C., Metcalf, C. A., Wang, Y., Sundaramoorthi, R., Keenan, T. P., Narula, S. S., & Dalgarno, D. C. (2005) · Springer eBooks · doi:10.1007/0-387-24532-4_11 · Cited by 2
“Elevated Src expression and/or activity has been correlated with tumor growth in specific cancers having ErbB2 or c-Met receptors (Maa et al., 1995; Mao et al., 1997; Biscardi et al., 1999), by studies using Src-specific antisenseDNA (Staley et al.”
BackgroundMadalageri, M., Sadashivanavar, V., Kinnal, R., Atchou, K., & Pai, K. S. R. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154083 · Cited by 1
Biology of Colorectal Cancer Liver Metastases
Wray, C. J., Shah, A. N., Berman, R. S., & Ahmad, S. A. (2008) · Springer eBooks · doi:10.1007/978-1-84628-947-7_2 · Cited by 1
CIP4 and Src in Promoting the Migration and Invasion of Breast Cancers
Pichot, C. S. (2010) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Clinical Development of Src Family Kinase Inhibitors in Malignant Melanoma
Macpherson, I. R., Jones, R. J., & Evans, T. R. J. (2007) · The Open Cancer Journal · doi:10.2174/1874079000701010009 · Cited by 1
“Therefore, elevated SFK activity may be secondary to activation of an upstream RTK to which it is coupled [39, 40].”
BackgroundIntra-cellular tyrosine kinase
Irby, R., & Yeatman, T. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.020
Self-citationEndofin is a novel component in EGF/EGFR oncogenic signaling
Toy, W., & Lim, Y. P. (2007) · Clinical Cancer Research
The Crucial Role of c-Src Tyrosine Kinase in Bone Metabolism
Peruzzi, B., Rucci, N., & Teti, A. M. (2012) · InTech eBooks · doi:10.5772/37995
“…(PDGF) (De Mali et al, 1999; Bowman et al, 2001), insulin-like growth factor (IGF)-1 (Arbet-Engels et al, 1999), fibroblast growth factor (FGF) (Landgren et al, 1995), colony-stimulating factor (CSF)- 1 (Courtneidge et al, 1993) and hepatocyte growth factor (HGF) receptors (Mao et al, 1997) (Fig.”
BackgroundThe role of Src kinase in renal cell carcinoma
Qayyum, T. (2014) · Enlighten: Theses (The University of Glasgow)
IAP Regulation of Tumor Metastasis: A Dissertation
Mehrotra, S. (2009) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/2ajg-8646
“…in its catalytic activity has been implicated in various types of cancers (Irby and Yeatman, 2000) and increased c-Src kinase activity has been implicated with enhanced metastatic potential (Mao et al., 1997; Talamonti et al., 1993) through effects on motility and invasion (Jones et al., 2002).”
BackgroundPastor, D. M., Poritz, L. S., Olson, T. L., Kline, C. L. B., Harris, L., Chinchilli, V. M., & Irby, R. (2010)
Self-citationPontillo, C. A. (2012) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Role of ErbB2 and ErbB4 in Cancer Growth, Prognosis and as Targets for Immunotherapy
Hollmén, M. (2010) · UTUPub (University of Turku) · Cited by 1
Le neuropeptide bombésine module la prolifération et l'invasion tumorale.
Saurin, J., Némoz-Gaillard, É., Ratineau, C., Chayvialle, J. A., & Abello, J. (2000) · médecine/sciences · doi:10.4267/10608/1760
“Les protéine-kinases p125FAK et src sont en particulier surexprimées dans les tumeurs primaires et les lignées cellulaires tumorales humaines, et cette augmentation d’expression est corrélée avec le potentiel métastatique des tumeurs [32, 33].”
BackgroundAbelson Kinase Based Regulation of Tumor Cell Invasion in HNSCC
Hayes, K. E. (2013) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.472
Extracting Fitness Relationships and Oncogenic Patterns among Driver Genes in Cancer
Zhang, X., Gao, L., & Jia, S. (2017) · Molecules · doi:10.3390/molecules23010039
Src Regulation of von Hippel-Lindau Tumour Suppressor Protein
Chou, M. T.-H. (2009) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/17055
Role of Src and VEGFR Tyrosine Kinases in Esophageal Cancer
Sushma, P. S. (2018) · Springer eBooks · doi:10.1007/978-981-13-1486-5_2
Identification and functional characterisation of novel APC/C interacting proteins
Sedgwick, G. G. (2010) · University of Birmingham Institutional Research Archive (University of Birmingham)
Data from Differing Src Signaling Levels Have Distinct Outcomes in Drosophila
Vidal, M., Warner, S., Read, R. D., & Cagan, R. L. (2023) · doi:10.1158/0008-5472.c.6496667
Nonreceptor Tyrosine Kinases and Their Roles in Cancer
Wiener, J. R., & Gallick, G. E. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1216-8_4
Gao, Z., Qiu, M., Yang, Z., Fang, X., Yin, G., Zhang, Q., Liu, J., Liu, R., Wang, Y., Liu, Y., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04256-9
“Studies have shown that the Src pathway is activated in more than 70% of colorectal tumors [33].”
Necroptosis: The Regulation Between EGFR and TNFR in Cancer
Kim, J. G., & Jin, W. (2026) · Cells · doi:10.3390/cells15141310
Metadata
- Authors
- Mao, W., Irby, R., Coppola, D., Fu, L., Wloch, M., Turner, J., Yu, H., Garcia, R., Jove, R., & Yeatman, T. J.
- Affiliations
- University of South Florida (US)
- Venue
- Oncogene
- Published
- 1997-12-18
- Volume
- 15
- Issue
- 25
- Pages
- 3083-3090
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2332502334
- Cited by
- 200
- References
- 0
- Citations by year
- 2026: 3 · 2025: 1 · 2023: 6 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 8 · 2016: 2 · 2015: 4 · 2014: 6 · 2013: 6 · 2012: 11
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ariad Pharmaceuticals
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- Src kinase, receptor tyrosine kinase, colon cancer, liver metastasis, EGFR, HER2/neu, c-Met, signal transduction, metastatic phenotype, protein kinase activation, EGFR inhibitors, feedback regulation
- MeSH terms
- Colonic Neoplasms, Colonic Polyps, Epidermal Growth Factor, Humans, Neoplasm Metastasis, Neoplasm Proteins, Phenotype, Phosphorylation, Protein Kinases, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Genes, src, Erb-b2 Receptor Tyrosine Kinases, Receptor Protein-Tyrosine Kinases, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.